Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced the appointment of Dave Daly as Chief Executive Officer. With more than 30 years of cancer diagnostics and executive leadership experience, including at Thrive Earlier Detection (acquired by Exact Science ‘EXAS’) and Foundation Medicine (acquired by Roche), Daly is ideally positioned to spearhead Exai’s accelerated product development and partnering strategy.
Exai Bio was founded on technology discovered and developed by UCSF researcher Hani Goodarzi, PhD.